What are the potential benefits of Somatostatin?

GH inhibition relevant to acromegaly management (via analogs). Glucagon and insulin secretion modulation. GI motility and secretion regulation. Neuroendocrine tumor symptom control. Reduction of splanchnic blood flow in GI bleeding. Pharmacological template for clinically successful analogs

What compounds work synergistically with Somatostatin?

Somatostatin has been studied alongside Octreotide, Lanreotide, Pasireotide for potential synergistic effects.

Somatostatin — Mechanism, Benefits, Research & Synergies

Overview

Somatostatin is a naturally occurring cyclic 14-amino acid neuropeptide (with an alternate 28-amino acid form) produced in the hypothalamus, pancreas, and gastrointestinal tract. It acts as a broad inhibitor of endocrine and exocrine secretion, suppressing growth hormone, TSH, insulin, glucagon, and multiple GI hormones. Its ultrashort plasma half-life of under three minutes drove the development of longer-acting synthetic analogs including octreotide, lanreotide, and pasireotide that are widely used in clinical practice.

Mechanism of Action

Somatostatin binds five receptor subtypes (SSTR1–SSTR5), all Gi/o-coupled GPCRs. Receptor activation inhibits adenylyl cyclase (reducing cAMP), activates inward-rectifying potassium channels (hyperpolarizing cells), and inhibits voltage-gated calcium channels. These combined effects suppress secretory cell activity across multiple tissues. SSTR2 and SSTR5 are the primary subtypes mediating GH inhibition and are the principal targets of therapeutic analogs.

Potential Benefits

GH inhibition relevant to acromegaly management (via analogs)
Glucagon and insulin secretion modulation
GI motility and secretion regulation
Neuroendocrine tumor symptom control
Reduction of splanchnic blood flow in GI bleeding
Pharmacological template for clinically successful analogs

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

IV infusion 250 mcg/hour for GI bleeding (short-term hospital use). Not used long-term due to rapid degradation; replaced by synthetic analogs in chronic conditions.

Amino Acid Sequence

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (cyclic, disulfide Cys3-Cys14)

Side Effects & Safety

Short-term IV use: nausea, diarrhea, abdominal cramping
Hypoglycemia or hyperglycemia (insulin/glucagon suppression)
Bradycardia at high doses

Synergistic Compounds

The following compounds have been studied alongside Somatostatin for potential complementary or synergistic effects:

OctreotideLanreotidePasireotide

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]
[object Object]

Quick Facts

Molecular Weight	1637.9 g/mol
Research Status	Parent compound of a major therapeutic drug class. Somatostatin itself is used short-term IV for GI bleeding. Long-acting analogs (octreotide, lanreotide) are FDA-approved for acromegaly and neuroendocrine tumors.

More Peptides in This Category

BPC-157 TB-500 GHRP-6 Hexarelin GHK-Cu Follistatin-344

Somatostatin